CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas

Linfeng Chen, Jing Ouyang, Kirsty Wienand, Kamil Bojarczuk, Yansheng Hao, Bjoern Chapuy, Donna Neuberg, Przemyslaw Juszczynski, Lee N. Lawton, Scott J. Rodig, Stefano Monti, and Margaret A. Shipp

Disclosures: This work was supported by a Mobility Plus fellowship from the Polish Ministry of Science and Higher Education (1261/MOB/IV/2015/0) (K.B.) and a Leukemia and Lymphoma Society SCOR award (M.A.S. and S.J.R.). Conflict-of-Interest Statements M.A.S. has received research funding from Bayer, Bristol-Myers Squibb and Merck; has served as a scientific advisor to Bristol-Myers Squibb and has received honoraria from AstraZeneca. S.J.R. has received research support from Bristol-Myers Squibb, Merck, KITE/Gilead Pharmaceuticals and Affimed Pharmaceuticals. P.J. has served as a scientific advisor and consultant for Selvita S.A.

Contributions: L.C., J.O., K.B. and M.A.S. designed the study. L.C., J.O., K.W., K.B., Y.H., P.J. and B.C. performed the experiments. L.C., J.O., K.W., K.B., D.N., S.J.R., S.M. and M.A.S. analyzed the data. L.C., J.O., K.W., K.B., L.N.L. and M.A.S. wrote the manuscript. All authors approved the final version of the manuscript.